health pharma news today obesity drugs glp-1 Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 drugs, which have grown

the public comment period runs through June 29, 2026, and a final determination has not yet been issued

While not approved specifically for weight loss, clinical trials showed average weight reduction of 3-5% of body weight, making it the least potent option in this category for weight management

Frederich R, Alexander JH, Fiodereck FT et al

We strongly believed in the potential of Wegovy pill to be the first oral GLP-1 for weight management to market, and we ensured that we could launch without any constraints, added Bennett

Estimating cardiovascular benefits of tirzepatide in sleep apnea and obesity: insight from the SURMOUNT-OSA trials